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ABSTRACT
Objective To determine the appropriateness of valproate 
prescribing indicators in England and Wales as a means 
of identifying variation in the prevalence of valproate use 
among women and girls of childbearing potential between 
health communities.
Methods and analysis Cross- sectional study using 
an ecological design using routinely published, publicly 
available valproate prescribing data for the period January 
to March 2019 and 2018 mid- year population estimates.
Results In England and Wales, 87.7 people in every 
1000 people prescribed valproate were women or girls 
aged 14–45 years (range 60.4–133.2). The prevalence of 
valproate use among all women and girls of childbearing 
age was 1.49 cases per 1000 women and girls aged 
14–45 years (range 0.47–3.13). Considerable variation 
in prevalence was observed depending on which of two 
measures was used. The relative risk of exposure between 
health communities increased from 2.2 to 6.6 depending 
on the measure used, leading to the identification of 
different health communities being a priority for action. 
Wide variation was observed in the prevalence of valproate 
use among individuals other than women and girls aged 
14–45 years (mean prevalence 3.89 cases per 1000 
population, range 2.42–7.78). The prevalence of valproate 
use in all Clinical CommissioningGroups and Local Health 
Boards was lower in the at- risk population than in the 
rest of the population (p=0.046) with a strong positive 
correlation observed between the prevalence of valproate 
use in these two groups (p<0.001).
Conclusion Current indicators may lead to a failure to 
systematically review women and girls of childbearing age 
prescribed valproate. Urgent consideration should be given 
to changing the indicators used in England and Wales.
INTRODUCTION
The harmful effects of prenatal exposure to 
sodium valproate (valproate) are well estab-
lished. Valproate’s teratogenic effects were 
first identified in the early 1980s1 with major 
congenital malformations known to occur 
in as many as 1 in 10 children exposed to it 
during pregnancy.2 Subsequently, exposure 
Key messages
What is already known about this subject?
 ► The harmful effects of prenatal exposure to sodium 
valproate (valproate) are well established.
 ► With increasing recognition of these risks, patient 
support groups have argued strongly for govern-
ment and medicines regulatory agencies to take de-
cisive action to reduce the risk of valproate exposure 
during pregnancy.
 ► Regulators are considering further action to restrict 
the use of valproate.
 ► The use of prescribing indicators is an accepted 
means of measuring the variation in prescribing be-
haviour and targeting intervention.
What does this study add?
 ► Determining appropriate prescribing indicators can 
be challenging. Identification of the population at 
risk is critical to the effectiveness of a prescribing 
indicator.
 ► There is considerable variation in the rate of val-
proate prescribing between health communities in 
England and Wales that may not be fully appreciated 
using currently used prescribing indicators.
 ► High overall rates of prescribing of valproate in some 
health communities may be masking high prescrib-
ing rates among the population most at risk from 
exposure.
How might this impact on clinical practice or 
future developments?
 ► The preferred solution to reducing exposure of 
women and girls at risk to valproate is individualised 
review and discussions between patients and their 
clinicians.
 ► Urgent consideration is needed to change the cur-
rent indicator of valproate prescribing to ensure 
that limited resources are targeted towards areas 
where prescribing prevalence is highest and where 
the likelihood of identifying those in whom valproate 
could be de- prescribed is greatest.
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in utero has been found to be associated with increased 
risk of autism spectrum disorder, attention- deficit hyper-
activity disorder and a 30%–40% risk of developmental 
disorder.3 4 With increasing recognition of these risks, 
patient support groups have argued strongly for govern-
ment and medicines regulatory agencies to take decisive 
action to reduce the risk of valproate exposure during 
pregnancy.5
Product information for medicines containing 
valproate has carried warnings about the possible risk of 
birth defects since the medicine was first licensed in 1974, 
and warnings have been progressively strengthened over 
time as new risks were identified.6 However, it was not 
until 2015 that the Medicines and Healthcare Products 
Regulatory Agency (MHRA) in the UK issued guidance 
that valproate use should be restricted not only during 
pregnancy but also in all women of childbearing potential 
‘unless clearly necessary’.7 Further measures, including 
updating product information, the production of educa-
tional materials and placing warnings on the packaging of 
valproate medicines, were taken between 2015 and 2018 
to first ensure women were better informed about the 
risks of taking valproate during pregnancy, and latterly 
to contraindicate its use in women and girls at- risk unless 
they were enrolled in a pregnancy prevention programme 
(PPP) (box 1).
Since the introduction of additional regulatory 
measures, the number of women and girls aged 14–45 
years receiving prescriptions for valproate in the UK has 
declined from approximately 35 000 per year between 
2010 and 20127 to 20 000 in 2018.8 However, the reduc-
tion in use among at- risk individuals has been slower than 
might have been anticipated given the nature of the regu-
latory response and consideration is now being given to 
further action to restrict use.8
The importance of making resources available to iden-
tify patients exposed to valproate in primary care has 
been argued by others9 and in 2018, the National Health 
Service Business Services Authority (NHSBSA) began 
publishing quarterly data on the number of women and 
girls of childbearing age who have received prescriptions 
for valproate. These measures are intended to contribute 
to the monitoring of the effectiveness of the MHRA’s 
regulatory measures and support the safe and appropriate 
use of valproate. The objective of this study was to deter-
mine the appropriateness of the valproate prescribing 
indicators in England and Wales as a means of identifying 
Clinical Commissioning Groups (CCGs) in England and 
Local Health Boards (LHBs) in Wales, with above- average 
rates of prescribing of valproate among women and girls 
of childbearing potential.
MATERIALS AND METHODS
This was a retrospective observational study using an 
ecological and cross- sectional design using routinely 
published valproate prescribing (for Wales) and 
dispensing (for England) data for the period January 
to March 2019 (‘the study period’) and population data 
for all CCGs and LHBs in England and Wales. Data for 
analysis were obtained in October 2019 from websites 
maintained by the NHSBSA, All Wales Medicines Strategy 
Group (AWMSG), Office of National Statistics (ONS) and 
Statswales.
Data sources
The number of patients dispensed a prescription for 
valproate, derived from prescriptions submitted to the 
NHSBSA for payment by pharmacies and dispensing 
doctors in England, for the period January to March 
2019, were taken from the NHSBSA’s website. Data 
were available aggregated by CCG.10 Similar data for 
Wales, providing the total number of patients prescribed 
valproate extracted from general practice (GP) clinical 
systems and aggregated by LHB, were available from the 
Box 1 Chronological order of MHRA regulatory action 
taken against valproate since 2015
January 20157
 ► Product information updated to reflect current understanding of 
available evidence.
 ► Educational materials made available to inform about risks associ-
ated with valproate.
 ► Valproate made a black triangle medicine subject to additional 
monitoring.
February 201628
 ► Updated educational materials disseminated to specialist prescrib-
ers, general practitioners and pharmacists.
 ► Confirmation that from later in 2016 outer packaging for medicines 
containing valproate will include a warning for women on the risk of 
adverse pregnancy outcomes.
April 201729
 ► Patient safety alert issued highlighting risks of valproate exposure 
to the unborn child.
 ► Organisations directed to undertake systematic identification of 
women and girls taking valproate and to use the MHRA resources to 
support them to make informed choices.
April 201830
 ► Notification that valproate medicines must no longer be used in 
women and girls of childbearing potential unless a pregnancy pre-
vention programme (PPP) is in place.
 ► Confirmation that visual warning symbol will be added to the carton 
of valproate medicines by September 2018 with advice to pharma-
cists to dispense in original containers.
 ► Introduction of new absolute contraindication for use of valproate 
medicines in pregnancy for the treatment of the bipolar disorder.
July 20198
 ► MHRA Board considers further regulatory measures as recommend-
ed by the Commission on Human Medicines:
Directly recalling women of childbearing age on valproate for spe-
cialist review.
A move towards close specialist supervision of prescribing of val-
proate to women of childbearing age.
 ► Confirmation of continuing work to establish a registry to track all 
women and girls taking valproate to measure compliance with the 
PPP.
MHRA, Medicines and HealthcareProducts Regulatory Agency.  on F
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AWMSG.11 12 Data for the number of women and girls 
aged 14–45 years who dispensed or prescribed valproate 
were also obtained for each CCG and LHB, respectively. A 
patient is included in the number of patients prescribed 
valproate, reported by the NHSBSA and AWMSG, if they 
had one or more prescriptions for valproate dispensed 
(England)/issued (Wales) during the study period. 
Patients who had multiple valproate prescriptions 
dispensed/issued are counted only once.
We used ONS mid- year population estimates for 2018,13 
for all CCGs in England and from the Statswales website 
for all LHBs in Wales,14 to estimate the population in 
each CCG and LHB during the study period.
Analysis
Our outcome was the prevalence of valproate use in each 
CCG and LHB. For CCGs, the prevalence of valproate 
use was calculated using the number of unique valproate 
users who had one or more prescriptions for valproate 
dispensed during the study period. For LHBs, where GP 
prescribing data were available but dispensing data were 
not, the prevalence was calculated using the number of 
unique valproate users who had one or more prescriptions 
issued by a GP during the study period. We were aware 
that differences in the method of calculating prevalence 
between CCGs and LHBs could lead to an overestimate of 
prevalence among LHBs (because some valproate users 
may not have their prescription dispensed) however, we 
considered that this would not impact on our analysis. 
This was because in order to be in the study cohort, a 
valproate user only needed to have one prescription 
dispensed during the study period and we assumed the 
number of users not having any prescription dispensed 
would be low. We were also mindful that the purpose of 
the study was to compare different measures of the prev-
alence of valproate use and any differences in our data 
would affect the different measures equally.
We calculated two alternative measures of the preva-
lence of valproate use among women and girls of child-
bearing potential. First, we reproduced the NHSBSA and 
AMWSG prescribing measures by calculating the number 
of women and girls aged 14–45 years receiving a prescrip-
tion for valproate as a proportion of all patients receiving 
valproate for each CCG and LHB. Second, we calcu-
lated an alternative measure, the prevalence of valproate 
prescribing among all women and girls aged 14–45 years 
(who we considered to be the ‘population at risk’ from 
exposure to valproate), for each health community using 
the ONS mid- year population estimates. CCGs and LHBs 
were ranked and allocated to deciles for each measure. 
For both measures, we used the calculated prevalence rate 
for each CCG and LHB to calculate the relative risk (RR) 
between the organisations with the highest and lowest 
prescribing prevalence. We also calculated the RR of 
receiving valproate between women and girls aged 14–45 
years and the rest of the population in each CCG and LHB 
(calculated by subtracting the number of women and girls 
aged 14–45 years from the total population). Differences 
in the RR and the ranking of individual CCGs and LHBs 
arising from the alternative methods for calculating the 
prevalence of valproate prescribing were described. We 
used z tests to calculate differences in the proportion 
of populations using valproate. Finally, we used linear 
regression to examine the association (Pearson’s Correla-
tion Coefficient) between the prevalence of valproate 
prescribing in women and girls aged 14–45 years, and the 
total population excluding women and girls aged 14–45 
years. Microsoft Excel (Microsoft Corporation 2016) was 
used to calculate simple descriptive statistics and Stata 
Statistical Software release V.16 (StataCorp. 2019) to 
calculate appropriate inferential statistics.
RESULTS
The total population of all CCGs and LHBs in England 
and Wales in the study period was 59.1 million. Of these, 
11.8 million (20.0%) were women and girls aged between 
14 and 45 years. A total of 201 415 unique valproate 
users were identified between January and March 2019 
giving rise to an overall prevalence of 3.41 cases per 
1000 population (range 1.94–6.93 cases per 1000 popu-
lation). Valproate prescribing was less frequent among 
women and girls aged 14–45 years than among the total 
population representing only 8.8% of all valproate users 
(17667/201415).
The proportion of valproate users at risk of prenatal exposure
Between January and March 2019, the mean prevalence 
of exposure to valproate among women and girls aged 
14–45 years was 87.7 cases per 1000 patients prescribed 
valproate (range 60.4–133.2). The RR in the highest prev-
alence CCG or LHB was approximately double that of the 
CCG or LHB with the lowest prevalence (RR=2.2).
The prevalence of valproate use among women and children 
of childbearing potential
Between January and March 2019, the mean prevalence 
of exposure to valproate among women and girls aged 
between 14 and 45 years (the population at risk) was 1.49 
cases per 1000 women and girls aged 14–45 years (range 
0.47–3.13). The RR between the CCGs and LHBs with 
the highest and lowest prevalence increased to 6.6, three 
times the variation observed when measuring prevalence 
as the proportion of all valproate users and with fewer 
CCGs and LHBs falling within two standard errors of the 
England and Wales prevalence rate (97/198 vs 167/198) 
(figure 1).
When we looked at the CCGs and LHBs in the highest 
prevalence decile (decile one) for each measure (n=20) 
(table 1), where we postulate action to reduce prevalence 
would be focused, we found little overlap between the 
health communities identified. Only six CCGs and LHBs 
(30%) appeared in the highest decile for both measures. 
The CCG that had the highest prevalence of all CCGs or 
LHBs using population at risk (all women aged 14–45 
years) as the denominator, was in fact below the mean 
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prescribing rate when measured using the approach 
adopted by the NHSBSA and AWMSG. We identified 
1808 women and girls at risk in decile one using propor-
tion of all patients prescribed valproate as the measure 
Figure 1 Funnel plots showing the distribution of mean prevalence of exposure to valproate among women and girls aged 
between 14 and 45 years in CCGs and LHBs in England and Wales, as a proportion of all valproate users (top) and the 
population at risk (bottom).
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(the current NHSBSA and AWMSG measure) and 1898 
using the prevalence of valproate use among all women 
and girls of childbearing potential. The prevalence of 
valproate prescribing in decile one was significantly 
higher in the CCGs and LHBs in decile one derived from 
the second measure (2.57 cases vs 1.94 cases, difference 
0.63 cases per 1000 women and girls at risk, 95% CI 0.01–
1.25, p=0.046).
The prevalence of valproate use excluding women and 
children of childbearing potential
Between January and March 2019, the mean prevalence 
of exposure to valproate among the population excluding 
women and girls of childbearing age was 3.89 cases per 
1000 population (range 2.42–7.78). The RR between the 
CCGs and LHBs with the highest and lowest rate of expo-
sure was 3.21.
The association between the rate of valproate prescribing in 
women and girls aged 14–45 years and the total population 
excluding women and girls aged 14–45 years
Positively we found the mean rate of valproate prescribing 
in England and Wales was lower in women and girls aged 
14–45 years than in the rest of the population (ie, when 
women and girls aged 14–45 years were excluded) (1.62 
vs 3.92 cases per 1000 population, difference −2.31, 95% 
CI −2.50 to −2.11, p<0.001). This was the case in all CCGs 
and LHBs (figure 2). However, we found a wide difference 
in the RR of being prescribed valproate among women 
and girls aged 14–45 years and the rest of the population, 
when we compared the CCGs or LHBs with the smallest 
and widest variations between the two groups. Overall, 
women and girls aged 14–45 years were 62% less likely 
to be prescribed valproate than the rest of the popula-
tion (RR=0.38), however, this ranged from a reduced like-
lihood of 82% to just 35% (RR range 0.18–0.65) in the 
CCG with the smallest difference in prevalence between 
the two groups. A strong positive correlation was observed 
Table 1 Clinical commissioning groups (England) and Local Health Boards (Wales) in highest prevalence decile (n=20) of 
























NHS Blackpool CCG 966 79 81.78 25 243 3.13
NHS North East Lincolnshire CCG 792 88 111.11 29 347 3.00
NHS Great Yarmouth and Waveney CCG 1026 107 104.29 36 176 2.96
NHS Hastings and Rother CCG 906 85 93.82 30 691 2.77
NHS St Helens CCG 902 92 102.00 33 672 2.73
NHS North Cumbria CCG 1467 147 100.20 53 954 2.72
NHS Southport and Formby CCG 501 49 97.80 18 575 2.64
Abertawe Bro Morgannwg University Health 
Board
2624 265 100.99 102 342 2.59
NHS Wyre Forest CCG 453 44 97.13 17 028 2.58
NHS Knowsley CCG 764 78 102.09 30 322 2.57
NHS South Kent Coast CCG 816 91 111.52 35 957 2.53
NHS Newark and Sherwood CCG 533 54 101.31 21 578 2.50
NHS Durham Dales, Easington and Sedgefield 
CCG
1324 121 91.39 48 792 2.48
NHS South West Lincolnshire CCG 445 51 114.61 21 688 2.35
NHS Bradford City CCG 456 50 109.65 21 416 2.33
NHS South Tees CCG 1247 124 99.44 53 162 2.33
NHS Hull CCG 1208 131 108.44 56 415 2.32
NHS Halton CCG 550 58 105.45 25 170 2.30
Cwm Taf University Health Board 1640 136 82.93 59 839 2.27
NHS Isle of Wight CCG 547 48 87.75 21 464 2.24
England and Wales total 201 415 17 667 87.71 11 828 753 1.49
CCG, Clinical Commissioning Group; LHB, Local Health Board; NHS, National Health Service.
 on F











6 Evans A, et al. Integ Health J 2020;2:e000022. doi:10.1136/ihj-2019-000022
Open access 
between the prevalence of valproate prescribing to 
women and girls aged 14–45 years and the prevalence of 
valproate prescribing in the rest of the population in the 
respective CCG or LHB (Pearson’s correlation r=0.4738, 
n=198, p<0.001) (figure 2). We found that higher rates of 
valproate prescribing among women and girls aged 14–45 
years are a consequence of higher rates of valproate 
prescribing in general.
Discussion
This study examined the appropriateness of valproate 
prescribing indicators in England and Wales as a means 
of identifying variation in the prevalence of valproate 
use among women and girls of childbearing potential 
between health communities.
Our findings demonstrate the importance of appro-
priate indicator selection to support reducing variation 
in valproate use between CCGs and LHBs. We found that 
current prescribing indicators do not adequately support 
identifying those CCGs and LHBs in which there is a high 
prevalence of valproate use among women and girls of 
childbearing age when differences in the population 
structure of individual health communities are accounted 
for using accepted epidemiological techniques.
The concept of the population at risk is an important 
one in epidemiology because it accounts for absolute 
differences in the prevalence of a disease that arise 
between study populations as a result of demographic 
differences in the make- up of those populations. This is 
fundamental to making meaningful comparisons.15 By 
definition, the ‘population at risk’ can only include those 
people who are potentially susceptible to the disease being 
studied. Given in this study, we are concerned with the 
harms associated with exposure in utero, the population 
at risk cannot include men, or women and girls who are 
not of childbearing age. This problem has been referred 
to previously as the ‘floating numerator’.15 Our findings 
add weight to previous studies demonstrating how the 
omission or use of inappropriate denominators leads to 
fallacious conclusions being inferred from research.16 17
In this study, we have been able to demonstrate that 
in areas where absolute numbers of women and girls 
prescribed valproate are higher; this in the vast majority 
of CCGs and LHBs simply reflects higher rates of 
valproate prescribing among the general population. It is 
important to point out that we do not believe that there 
is anything particularly remarkable about this finding, 
indeed we believe that it is entirely intuitive because we 
are not aware of any compelling reason for valproate to 
Figure 2 Scatter plot showing the association between the prevalence of valproate prescribing to women and girls 
aged 14–45 years and the rate of valproate prescribing in the rest of the population all CCGs and LHBs. CCG, Clinical 
CommissioningGroup; LHB, Local Health Board
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be prescribed more frequently in, for example, women 
than men.
Given this is the case, we find the choice of the denom-
inator in the existing NHSBSA and AWMSG indicators 
somewhat surprising. Not only does it differ from that 
used by the MHRA to measure the reduction in valproate 
use over time, but it also misapplies the generally 
accepted principles of measuring disease frequency with 
worrying results. Continued use of the existing NHSBSA 
and AWMSG indicators may mean some health communi-
ties, which we consider should be a priority for interven-
tion, may not be identified because the high prevalence 
of valproate prescribing among women and girls of child-
bearing age is masked by a high prevalence among men 
and women not in the population at risk. Given this is the 
case, we believe that the indicator chosen by the NHSBSA 
and AWMSG while able to identify health communities 
with wide differences in the prevalence of valproate use 
between the at- risk and the rest of the population is 
unlikely to identify any notable differences in prescribing 
rates in the population at risk between health commu-
nities. We argue that the most appropriate denominator 
would not be all persons prescribed valproate, but all 
women and girls aged 14–45 years; a similar measure has 
been adopted for use in Scotland.18
Data sharing and benchmarking against key indicators 
is an effective tool to support quality improvement and is 
widely used in the NHS. Prescribing indicators have been 
used in the NHS for over 30 years to measure the quality 
and effectiveness of prescribing in GP.19 20 Although 
there is some evidence of the effectiveness of the role of 
prescribing indicators in supporting improving quality in 
prescribing21 particularly where they form part of multi-
faceted interventions,22 23 they have been most commonly 
used to monitor changes in prescribing behaviour and 
cost over time.24 Being shown to be an outlier can be an 
‘eye opener’ and highlight priority areas for local action 
to change prescribing behaviour and improve quality. 
Conversely, clinicians may be falsely reassured where their 
performance appears better than or similar to their peers 
and this may lead to the continuation of current (unsafe) 
practice. It is therefore paramount that data and anal-
yses are robust in order to identify areas for review and 
to motivate organisations and prescribers where change 
is needed.
We found wide differences between CCGs and LHBs in 
the rate of valproate use among the overall population 
suggesting some health communities have been more 
successful than others in reducing valproate use. Under-
standing the reasons for the relative success of these 
organisations may provide useful insight for those appar-
ently not addressing the issue at hand. Although it was 
not within the scope of this study to explore the reasons 
for this finding, we suggest it is one that would benefit 
from further research because such wide variation cannot 
be explained easily. This might examine, for example, 
whether differences can be attributed to differing popu-
lation structures or whether they are associated with 
local commissioning arrangements for or availability of 
neurology services.
We believe the main strength of this study is that it 
combines routinely published valproate prescribing and 
dispensing data with population data to draw attention 
to the importance of applying epidemiological principles 
to the development of prescribing indicators. However, 
the study is not without limitations. The ecological design 
means that although we found a significant positive asso-
ciation between the prevalence of valproate use among 
women and girls of childbearing age and the prevalence 
among the total population excluding women and girls 
aged 14–45 years, in each health community, this will not 
necessarily be true in individual GPs in those communi-
ties. We cannot therefore rule out the effect of chance on 
variation between health communities. We recommend 
future work should use GP in addition to aggregated data 
in an appropriate mixed- effects model to address this. 
The treatment of epilepsy, for which valproate is most 
commonly prescribed, is likely to be led and strongly 
influenced by the availability (or lack of availability) of 
hospital neurology services. The use of GP data to produce 
prescribing indicators assumes that GPs are responsible 
for and willing to act on unwarranted variation; in this 
therapeutic area, we think this is unlikely without addi-
tional specialist input. A final limitation is that the publicly 
available data used to estimate the number of women and 
girls of childbearing age exposed to valproate will both 
include individuals who are part of the valproate PPP25 
and exclude those prescribed valproate by their hospital 
specialist rather than their GP. This means the number of 
women and girls at risk in our analysis is likely to overstate 
the actual number at risk.
A targeted universalism26 approach is necessary to mini-
mise fetal exposure to valproate and reduce the risk of 
congenital malformation, developmental and behavioural 
disorders. The statements issued by MHRA insisting that 
valproate medicines are only prescribed if other treat-
ments are ineffective or not tolerated and only then if 
the conditions of the PPP are met, apply to all clinicians. 
Ranking CCGs and LHBs using relative differences in 
prevalence draws attention to a minority of outliers when 
in reality there will be women and girls exposed unneces-
sarily to valproate in every health community. All those at 
risk require urgent review.
There are, however, challenges to compliance with the 
requirements and a commitment to their implementation 
is required. Given limited specialist capacity to oversee 
changes to prescribing, prioritisation will be necessary 
along with wider consideration of how to develop and 
enhance skills among the wider team to support this work. 
The Clinical Practice Research Datalink, a real- world 
research service supporting retrospective and prospec-
tive public health and clinical studies sponsored by the 
MHRA and the National Institute for Health Research, 
and Royal College of General Practitioners have recently 
produced resources to support individual GPs to audit 
their valproate prescribing. This is a positive step that 
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it is hoped will support efforts to reduce the number of 
women and girls exposed to valproate.27
Despite a concerted effort on the part of regulators, 
the NHS and patient groups, many women are simply 
unaware of the risks of valproate in pregnancy. Taking 
further regulatory action, perhaps even going so far as 
to revoke valproate’s license, would deny some women 
the informed choice between continuing to use it and 
switching to a potentially less effective alternative. The 
preferred solution must be for individualised review and 
discussions between patients and their clinicians.
Although not without their limitations, prescribing 
indicators have an important role in helping prioritise 
where to place more intensive efforts to reduce risk, we 
are concerned that the current indicator may be giving 
false reassurance to clinicians failing to systematically 
review and where appropriate change treatment for 
women and girls of childbearing age. We recommend 
urgent consideration be given to changing the indicator 
used in England and Wales as we describe.
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